Headache lacosamide

Lacosamide Enhances slow inactivation of Na + channels blocks effect of neurotrophins (via CRM P-2) Well absorbed minimal protein binding one major nonactive metabolite t /2 12-14 h Generalized tonic-clonic seizures, partial seizures Toxicity Dizziness, headache, nausea small increase in PR interval Interactions Minimal... 

In an open study of lacosamide in 69 patients with painful diabetic neuropathy the initial dose was followed by escalation by 100 mg/day up to a maximum of 400 mg/day [132 ]. Patients then entered a 20-week maintenance period after which they could opt to continue for up to about 2.5 years. The most commonly reported adverse events that were considered possibly related to the trial medication were headache (7%), dizziness (7%), tremor (4%), fatigue (6%), and diarrhea and nausea (4%). The adverse events occurred most often during the titration period. Seven patients withdrew because of adverse effects—electrocardiographic changes (n =2), dizziness and nausea (n = 1), chest pain and nausea (n = 1), dizziness, fatigue, and tinnitus (n = 1), possible stroke and convulsion (n = 1, this was considered a serious adverse event), accidental overdose (n = 1). 

In a multicenter, randomized, placebo-controlled, double-blind trial in 495 patients with painful diabetic neuropathy who took lacosamide 200, 400, or 600 mg/day for 12 weeks after a 6-week titration phase, the lacosamide 400 mg/day group had significant improvement in the primary efficacy measure [136 ]. The most common treatment-emergent adverse events included dizziness, nausea, fatigue, headache, and tremor and all appeared to be dose-related. For example, the incidence of dizziness was 5% at 400 mg/day and 22% at 600 mg/day. There was nausea in 5% of patients taking 400 mg/day and 12% of those taking... 

Observational studies So-called third generation antiepileptic medications include retigabine, lacosamide, and esli-carbazepine. All three AEDs have linear pharmacokinetics and rapid absorption. The most common adverse effects observed with lacosamide versus placebo were dizziness, headache, diplopia, and nausea with retigabine, they were dizziness, somnolence, and fatigue and with eslicarbazepine acetate, dizziness and somnolence were reported [26 ]. 

Observational studies A multicenter prospective study of patients taking lacosamide reported the following adverse effects dizziness (6.8%), headache (5.9%), somnolence, vomiting, and dyspepsia in 4.3% each, irritability (3.4%), and diplopia, paresthesias, balance disorder, and fatigue in less than 2% each [70 ]. 

---